Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Yes | TR-015 | 133-06-2 | Captan | Mice | B6C3F1 | Female | Dosed-Feed | Intestines (Small) | Positive | Positive | (POLYPOID CARCINOMA) | Neoplastic Lesions |
Yes | TR-015 | 133-06-2 | Captan | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Small) | Positive | Positive | (POLYPOID CARCINOMA) | Neoplastic Lesions |
Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 0/35 1/65 2/50 | Neoplastic Lesions |
Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
Yes | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 1/50 0/50 0/50 3/50 | May Have Been Related |
Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
Yes | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Intestines (Small) | Some Evidence | Some Evidence | CARCINOMA 0/50 1/50 2/50 4/50 ADENOMA OR CARCINOMA 1/50 2/50 4/50 6/50 | Neoplastic Lesions |
Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | (Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50 | May Have Been Related |
Yes | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Mice | B6C3F1/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | Duodenum: adenoma (0/50, 0/50, 2/50, 13/50, 12/50); carcinoma (0/50, 0/50, 0/50, 1/50, 6/50); Jejunum: adenoma (0/50, 1/50, 0/50, 2/50, 5/50); Duodenum, Jejunum, or Ileum: adenoma (0/50, 1/50, 2/50, 15/50, 16/50), carcinoma (1/50, 0/50, 2/50, 3/50, 7/50), adenoma or carcinoma (1/50, 1/50, 4/50, 17/50, 22/50) | Neoplastic Lesions |
Yes | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Mice | B6C3F1/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | Duodenum: adenoma (1/50, 0/50, 1/50, 5/50, 15/50); Duodenum, Jejunum, or Ileum: adenoma (1/50, 1/50, 1/50, 5/50, 17/50), carcinoma (0/50, 2/50, 1/50, 3/50, 5/50), adenoma or carcinoma (1/50, 3/50, 2/50, 7/50, 20/50) | Neoplastic Lesions |
Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 3/50 | Neoplastic Lesions |
Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 0/35 1/65 2/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 3/35 6/65 3/50 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50 | May Have Been Related |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50 | Neoplastic Lesions |
No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/35 3/65 1/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 6/65 8/50 | Neoplastic Lesions |
Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | Neoplastic Lesions |
No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | Neoplastic Lesions |
No | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Rats | F344/N | Male | Dosed-Feed | Forestomach | Some Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 0/50 | May Have Been Related |
Yes | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 1/50 0/50 0/50 3/50 | May Have Been Related |
No | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/50 2/50 1/50 1/50 OR CARCINOMA 0/50 1/50 0/50 0/50 COMBINED 0/50 3/50 1/50 1/50 | May Have Been Related |
No | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 7/49 12/50 17/49 41/49; CARCINOMA 5/49 5/50 6/49 12/49 | Neoplastic Lesions |
No | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 16/50 19/50 17/50 40/50; CARCINOMA 7/50 3/50 8/50 17/50 | Neoplastic Lesions |
No | TR-430 | 28407-37-6 | C.I. Direct Blue 218 | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Some Evidence | Some Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 5/51; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 1/51; BASOSQUAMOUS TUMOR BENIGN 0/50 0/50 0/50 1/51 | Neoplastic Lesions |
No | TR-015 | 133-06-2 | Captan | Rats | Osborne Mendel | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
No | TR-015 | 133-06-2 | Captan | Rats | Osborne Mendel | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
Yes | TR-015 | 133-06-2 | Captan | Mice | B6C3F1 | Female | Dosed-Feed | Intestines (Small) | Positive | Positive | (POLYPOID CARCINOMA) | Neoplastic Lesions |
Yes | TR-015 | 133-06-2 | Captan | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Small) | Positive | Positive | (POLYPOID CARCINOMA) | Neoplastic Lesions |
No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Equivocal Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA 6/50 4/50 9/50 12/50 | May Have Been Related |
No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Some Evidence | Equivocal Evidence | MALIGNANT LYMPHOMA 2/50 2/50 2/50 5/50 | May Have Been Related |
Yes | TR-540 | 7220-79-3 | Methylene blue trihydrate | Mice | B6C3F1 | Male | Gavage | Intestines (Small) | Some Evidence | Some Evidence | CARCINOMA 0/50 1/50 2/50 4/50 ADENOMA OR CARCINOMA 1/50 2/50 4/50 6/50 | Neoplastic Lesions |
No | TR-540 | 7220-79-3 | Methylene blue trihydrate | Rats | F344/N | Male | Gavage | Pancreas Islet Cell | Some Evidence | Some Evidence | ADENOMA 4/50 9/50 12/50 8/50 ADENOMA OR CARCINOMA 4/50 9/50 14/50 8/50 | Neoplastic Lesions |
Yes | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Mice | B6C3F1/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | Duodenum: adenoma (0/50, 0/50, 2/50, 13/50, 12/50); carcinoma (0/50, 0/50, 0/50, 1/50, 6/50); Jejunum: adenoma (0/50, 1/50, 0/50, 2/50, 5/50); Duodenum, Jejunum, or Ileum: adenoma (0/50, 1/50, 2/50, 15/50, 16/50), carcinoma (1/50, 0/50, 2/50, 3/50, 7/50), adenoma or carcinoma (1/50, 1/50, 4/50, 17/50, 22/50) | Neoplastic Lesions |
Yes | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Mice | B6C3F1/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | Duodenum: adenoma (1/50, 0/50, 1/50, 5/50, 15/50); Duodenum, Jejunum, or Ileum: adenoma (1/50, 1/50, 1/50, 5/50, 17/50), carcinoma (0/50, 2/50, 1/50, 3/50, 5/50), adenoma or carcinoma (1/50, 3/50, 2/50, 7/50, 20/50) | Neoplastic Lesions |
No | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell carcinoma (0/50, 0/50, 0/50, 2/50, 11/50); squamous cell papilloma or carcinoma (1/50, 1/50, 0/50, 2/50, 11/50) | Neoplastic Lesions |
No | TR-546 | 7789-12-0 | Sodium dichromate dihydrate (VI) | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell carcinoma (0/50, 1/50, 0/49, 0/50, 6/49); squamous cell papilloma or carcinoma (0/50, 1/50, 0/49, 0/50, 7/49) | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Equivocal Evidence | malignant mesothelioma 0/50 1/50 1/50 0/50 | May Have Been Related |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | All Organs | Clear Evidence | Clear Evidence | hemangioma or hemangiosarcoma 4/50 6/50 6/50 11/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 28/50 23/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | All Organs | Some Evidence | Some Evidence | mononuclear cell leukemia 10/50 11/50 13/50 25/50 | Neoplastic Lesions |
Yes | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | (Duodenum, Jejunum, or Ileum): carcinoma 1/50 1/50 1/50 3/50 | May Have Been Related |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Male | Inhalation | Kidney | Clear Evidence | Clear Evidence | renal tubule adenoma 0/50 5/50 19/50 10/50 renal tubule carcinoma 0/50 7/50 31/50 18/50 renal tubule adenoma or carcinoma 0/50 11/50 37/50 27/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | Kidney | Clear Evidence | Clear Evidence | renal tubule carcinoma 0/50 2/50 1/49 1/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Male | Inhalation | Liver | Clear Evidence | Equivocal Evidence | hepatocholangiocarcionoma 1/50 2/50 2/50 3/50 | May Have Been Related |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 25/50 21/50 36/50 29/50 hepatocellular carcinoma 8/50 14/50 12/50 17/50 hepatocellular adenoma or carcinoma 28/50 30/50 37/50 38/50 hepatocholangiocarcinoma 0/50 1/50 1/50 2/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Mice | B6C3F1/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | alveolar/bronchiolar carcinoma 1/50 2/50 7/50 5/49 | May Have Been Related |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Male | Inhalation | Nasal Cavity | Clear Evidence | Clear Evidence | respiratory epithelium, adenoma 0/49 0/50 1/50 4/50 | Neoplastic Lesions |
No | TR-582 | 75-35-4 | Vinylidene Chloride | Rats | F344/N | Female | Inhalation | Thyroid Gland C-Cell | Some Evidence | Some Evidence | adenoma 3/50 4/50 6/48 11/50; carcinoma 0/50 6/50 2/48 2/50 adenoma or carcinoma 3/50 10/50 8/48 13/50 | Neoplastic Lesions |